SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 42.47 |
Enterprise Value ($M) | 69.82 |
Book Value ($M) | 95.23 |
Book Value / Share | 4.40 |
Price / Book | 0.45 |
NCAV ($M) | 9.70 |
NCAV / Share | 0.45 |
Price / NCAV | 4.38 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.31 |
Return on Assets (ROA) | -0.28 |
Return on Equity (ROE) | -0.30 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.30 |
Current Ratio | 3.30 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 18.68 |
Assets | 104.22 |
Liabilities | 8.98 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | University Of Texas/texas Am Investment Managment Co | |||
13D/A | Satter Muneer A | 4.90 | -18.34 | |
13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 | |
13G/A | Kapnick Scott | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
31,634 | 71,913 | 43.99 | |
20,985 | 41,605 | 50.44 | |
7,465 | 63,779 | 11.70 | |
31,771 | 221,677 | 14.33 | |
(click for more detail) |
Similar Companies | |
---|---|
RGLS – Regulus Therapeutics Inc. | RMTI – Rockwell Medical, Inc. |
RNAZ – TransCode Therapeutics, Inc. | RNXT – RenovoRx, Inc. |
RVPH – Reviva Pharmaceuticals Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io